Objective. Although quality indicators for the care of patients having acute myocardial infarction have been described for other countries, there are none specifically tailored to the Chinese health-care system. The study objective was to develop quality indicators for acute myocardial infarction in China, which measure and improve the quality of care for this patient population, and which could be reported on performance reports.
Introduction
There is a large disparity between the optimum standards of care and the actual care that patients receive in hospital when experiencing acute myocardial infarction (AMI) [1] [2] [3] . Clinicians' understanding of AMI and its treatment has undergone a significant change over the past several decades. New clinical advances are continuously emerging and many have proved to be very effective. However, the implementation of these changes into clinical practice has often lagged behind their development [4] .
To narrow this gap, many countries and regions have developed quality indicators to quantify and measure the quality of AMI health care [5] . Assessment of the quality of health-care delivery is playing an increasingly prominent role in contemporary medical practice. The application of quality indicators for AMI in some western countries has produced valuable insights into their feasibility, ease of use and the type of data required. They have also demonstrated their ability to identify variations in care across hospitals and have helped some institutions to improve their quality of care [6] [7] [8] [9] [10] . Peterson has reported that composite guideline adherence rates are associated with in-hospital mortality; observed mortality rates decreased from 6.31% for the lowest adherence quartile to 4.15% for the highest adherence quartile [11] . Although an association between care processes and outcomes was found, AMI process measures capture only a small proportion of the variation in hospitals' riskstandardized short-term mortality rates [12, 13] . Thus, there is a need to develop performance measures that are tightly linked to patient outcomes. However, it is not possible to use these ready-made indicators in Chinese hospitals. It should be acknowledged that there are many differences between China and these other countries when comparing health-care systems and how diseases are treated. China is a developing country. The once publicly funded and government-managed system has now changed to a market-oriented system; this has led to a healthcare system, which serves a small proportion of the population who can afford health insurance. Many patients with AMI cannot afford adequate care because the therapies are expensive (e.g. coronary angiography and primary percutaneous coronary interventions). Consequently, the ability of the patient to pay often determines if and when they receive care. Many patients do not select interventional therapies and elect for alternative modalities, including traditional Chinese treatments [14] .
In 2001, the Chinese Society of Cardiology of the Chinese Medical Association and the editorial boards of the Chinese Journal of Cardiology and the Chinese Circulation Journal combined data from clinical trials using evidence-based medicine and Chinese-specific conditions, and then referred to the American College of Cardiology and the American Heart Association (ACC/AHA) Guidelines for the Management of Patients With AMI (updated in 1999), finally developed to Chinese guide the diagnosis and treatment of patients with AMI [15] . In 2007, the committee used the practice guidelines from ACC/AHA and the European Society of Cardiology to publish Chinese guidelines about the management of patients with unstable angina and non-ST-elevation myocardial infarction [16] . After the guidelines were issued, Chinese articles reported that the prevalence of various AMI complications and hospital mortality had decreased, secondary prevention had improved leading to better myocardial infarction prognosis, and the management of AMI patients had become more standardized [17 -19] . However, these papers also showed that clinical practice did not always fully comply with the practice guidelines recommendations, and that there were large differences in practice. This means that more effort should be made around AMI quality improvement.
Clinical practice guidelines were reviewed along with the available evidence to produce quality indicators to guide patient care and to reduce adverse outcomes [8, 20, 21] . Scott et al. [10] also suggested that clinical guidelines combined with feedback from clinical indicators were useful for improving quality of care. However, there is neither a quality improvement project nor a set of performance measures in China. Previous quality measurements in Chinese hospitals have only used patient outcome indicators (e.g. hospital mortality, 30-day mortality). But there are a number of reasons which limit the use of these outcomes as measures of care quality. For instance, they often overlook processes of care and the hospital environment [22, 23] . Our goal was to identify and develop a set of quality indicators for the care of patients with AMI which are suitable for the Chinese healthcare system. To achieve this, we used a validated process which combined the available scientific evidence and consensus expert opinion to develop a multi-dimensional quality evaluation system specific to Chinese hospitals. It included hospital structures, processes of care and patient care outcomes to facilitate a way of improving clinical care. This new set of indicators provides an opportunity to assess health-care quality in AMI and represents an initial step toward the important goal of improving care in this patient population.
Methods

Delphi consensus panel
An attempt was made to create an expert panel that was sufficient diversity and included not only experts in cardiology but also administrators with experience in improving quality of care for patients with AMI. Potential indicators were rated by each panel member using a modified Delphi process. The multidisciplinary panel consisted of 17 members, including 6 thoracic and cardiovascular surgeons and 11 cardiovascular internists from 7 hospitals in Beijing and Harbin. To review the overall quality of AMI care, experts were selected from different disciplines: 12 held senior professional roles and 5 were associate senior professionals. Five of the panelists worked in hospital administration. All of the experts had an MD (for the names and background of the panelists, see Appendix 1).
Potential quality indicators
The potential indicators were divided into either hospital structural indicators, process of care indicators or outcome indicators. Structural indicators were defined as the environmental or technical aspects of patient care. Process indicators, or clinical performance measures, included how clinicians treated patients. Outcome indicators were defined as changes in the patients' health status. The ACC/AHA recommended that structural aspects of AMI care include prehospitalization, emergency department, inpatient and outpatient care, and discharge planning [24, 25] . Moreover, because the outcomes for AMI patients are closely related to treatment urgency [26 -28] , when choosing the structural indicators, we focused on the pre-hospital care and emergency services, which helped patients to receive treatment in the shortest possible time. Process of care indicators were based on pharmacological and non-pharmacological treatments recommended in the clinical practice guidelines. These guidelines were reviewed against the available literature evidence to help guide patient care. They used processes that have been verified in published multi-center randomized controlled trials (e.g. clopidogrel and angiotensin-receptor blockers). Using the literature review, expert interviews and hospital surveys, we identified and developed an initial list of potential quality indicators for AMI care, which could then be rated by the panel of experts.
Phase 1 of Delphi panel process: definition
Four panelists and two bio-statisticians from Harbin were invited to the first face-to-face meeting to discuss the definitions of each indicator, their clinical significance, the calculation and data collection methods, and how to use indicators. Indicators of similar meaning were the first to be screened. For all the indicators, eligible patients were defined as those who did not have any of the exclusion criteria (e.g. clinical contraindications to a particular intervention).
Phase 2 of Delphi panel process: rating of potential quality indicators
A rating questionnaire of all the indicators was developed and sent to panel members. To elicit their expert opinion, panelists were asked to rate each potential indicator according to the following characteristics: evidence-base, usefulness, interpretability, validity, ability to prevent the outcome, feasibility and an overall assessment [5, 29, 30] . For each characteristic, a 5-point scale was used: disagree (rating ¼ 1), moderate agreement (rating ¼ 2-4) and agreement (rating ¼ 5) (Tables 1 and 2) .
Firstly, each panel member rated each individual indicator on the top six characteristics using the 5-point scale against the attributes for good quality indicators. Then the rating results of the last question on the rating form, overall assessment, were used to make the final determination for inclusion of a potential indicator. After this round, indicators with an arithmetic mean score of .4 in the overall assessment group were considered for the discussion round with the panelists.
Phase 3 of Delphi panel process: developing quality indicators
At the second round of face-to-face discussions, the results from the initial round of ratings were presented to the experts. Panelists discussed various aspects of the indicators. First, panelists reviewed the evidence-base of each indicator, including the various clinical trials supporting their efficacy, and the clinical practice guidelines and relevant literature. The focus was on whether these indicators could be adapted to the Chinese health-care environment and to elucidate the reasons why they might or might not be suitable. Concurrently, the methodology for reporting the indicators was identified; for example, how each indicator was calculated and how regional differences could be taken into account. If Delphi panel members considered that an indicator was not suitable for the Chinese medical environment, they were excluded. The final opinions of the experts were collated when they reached a consensus. Definitions for the final indicators are available in Appendix 2.
Results
Using the literature reviews and the first round of face-to-face discussions, a rating questionnaire incorporating 
Structural indicators
Structural indicators can be used to review a hospital's scientific administration, the soundness of its rules and regulations, its advanced medical facilities and the rationale behind the allocation of human resources. However, it is difficult to provide quantified results about these aspects. This study used three emergency treatment indicators that focused on the cooperation between the emergency departments and inpatient areas within hospitals; the first two indicators reflected their collaborative responsiveness: (1) patients eligible for thrombolysis who arrive at hospital within 30 min of a call for emergency medical services and (2) pre-hospital 12-lead electrocardiogram (ECG). The third indicator, median length of emergency stay, partially represented the ability of emergency department protocols to promote the rapid identification and treatment of AMI patients. These indicators need to be met in order to provide the best outcomes for patients when visiting for medical assistance (Table 3) .
Process indicators
There are four medication indicators to evaluate for inpatient procedures, including aspirin, clopidogrel, beta-adrenoceptor blocking agents and thrombolytic therapies; three of these (aspirin, beta-adrenoceptor blocking agents and thrombolytics) relate to the indicators for STEMI/NSTEMI as recommended by AHA/ACC. These medicines are part of the primary recommendations for the medical management of AMI. Their effectiveness and serviceability for reducing the mortality of patients with AMI have been demonstrated. There are diagnostic and surgical treatment interventions in the non-drug therapy indicators, from which it is reasonable to infer that diagnostic procedures are also important. Thirdly, attention has also been paid to secondary prevention using six indicators that target the time of discharge from hospital; these have been widely used in the USA and Canada. Finally, minimum limits around the duration of medicine use were not introduced in this evaluation process (Table 4) .
Outcome indicators
Previously, in-hospital mortality has been used as the sole indicator to evaluate the quality of care. However, in-hospital mortality varies between hospitals due to the different proportions of patients with severe or acute disease. In this study, five indicators were selected to reflect the patient outcomes and treatments using different approaches ( For two of the inpatient process of care indicators, primary percutaneous coronary interventions (PCI) and thrombolytics received within 30 min of hospital arrival, there is a timing measure for thrombolytic use but not for primary PCI. This is because PCI is so expensive that many eligible patients cannot afford it in the short term, but thrombolysis may be acceptable. Chinese clinicians are often unable to select optimal treatments for patients in relation to the acuity of their illness. As a result, many specialists unanimously agreed that a timing measure for PCI was not feasible for doctors or hospitals in China. However, not also all patients receive coronary angiography based on economic conditions; clinicians still recommend it for definitive diagnosis and risk stratification. As a stronger Chinese health-care system becomes established over time, these indicators may require revision and updating.
Regarding secondary prevention, the Canadian tool focuses attention on the duration of drug use post-discharge. For instance, adherence to beta-blocker therapy 1 year after discharge and the number of prescriptions for statins filled within 90 days after discharge; these are also not feasible in China. Chinese doctors do not have contact with patients after discharge because hospitals lack systems for follow-up; they only write out prescriptions for patients at discharge and advise patients when to attend appointments post-discharge. As a consequence, Chinese clinicians rarely know patient outcomes after discharge. Thus, to obtain 30-day mortality is difficult, so in-hospital mortality is rated higher than 30-day mortality in terms of ease of data collection.
In North America, many hospitals have routinely reported quality indicators to compare and assess hospitals [34] . Through comparison and assessment, quality of care is continuously improved, as seen with the reduction of in-hospital mortality from cardiovascular disease [11, 35, 36] . Although we have developed a set of indicators to be used in China, we will face difficulties in their promotion and application. They could require hospitals and clinicians to finance more resources and to make an effort to learn and improve their medical techniques. Busy economically oriented hospitals may not be very keen to invest in quality improvement. Therefore, hospital decision-makers could play an important role by providing more input into improving the quality of medical care. Our study may provide important information for generating research questions for future studies.
In the next phase of our quality improvement effort, we will collect data that permits the quality of AMI care to be assessed. In hospitals from Heilongjiang province and Beijing city, we will collaborate with clinicians on collecting medical records to calculate relevant indicators. Furthermore, we hope that our indicators will be adopted by hospitals and embedded into routine clinical care to promptly measure the quality of care and to help clinicians understand how performance can be improved.
We recognize that these quality indicators have certain limitations. Different users of these indicators may wish to tailor them to their own setting and they may not want to measure all of the indicators on a regular basis. These indicators are intended to guide practice and evaluation of care provided to AMI patients in hospital, but it is acknowledged that individual clinicians may make different decisions for individual patients outside the range of these indicators. Finally, to use these indicators to assess quality of care, valid and realistic benchmarks are required [6] . To date, these benchmarks have not been clearly established by clinical studies. In the future, more drugs and new non-drug treatments will be shown to be effective in clinical trials so medical practice guidelines will need to be updated [25] . Therefore, quality indicators will also need to be updated on an ongoing basis.
Funding
This study was funded by the National Natural Science Foundation of China [70873031 to 
